Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACCI: Atezolizumab in Refractory mCRC
NCT02873195Phase 2Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jul 2017
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Atezolizumab + Bevacizumab + Capecitabine with Placebo + Bevacizumab + Capecitabine (2 arms). Primary endpoint: Progression-Free Survival at 20 months. Started Jul 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02873195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873195.